视黄醇亚油酸酯 | 631-89-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 视黄醇亚油酸酯
• 英文名称: retinyl linoleate
• 英文别名: retinyl linolate；[(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] (9Z,12Z)-octadeca-9,12-dienoate
• CAS: 631-89-0
• 化学式: C₃₈H₆₀O₂
• 分子量: 548.893
• InChiKey: XJKITIOIYQCXQR-SCUNHAKFSA-N

物化性质

• 沸点：
  631.0±34.0 °C(Predicted)
• 密度：
  0.929±0.06 g/cm3(Predicted)
• LogP：
  14.529 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  13
• 重原子数：
  40
• 可旋转键数：
  21
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (Z,Z)-9,12-十八烷二烯酸二聚物 、 维生素 A 醋酸酯 在 novozyme 435 作用下， 以 甲苯 为溶剂， 反应 20.0h， 生成 视黄醇亚油酸酯
  参考文献：
  名称：

  An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans

  摘要：

  Isotope dilution is currently the most accurate technique in humans to determine vitamin A status and bioavailability/bioconversion of provitamin A carotenoids such as beta-carotene. However, limits of MS detection, coupled with extensive isolation procedures, have hindered investigations of physiologically-relevant doses of stable isotopes in large intervention trials. Here, a sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS) analytical method was developed to study the plasma response from coadministered oral doses of 2 mg [C-13(10)]beta-carotene and 1 mg [C-13(10)]retinyl acetate in human subjects over a 2 week period. A reverse phase C-18 column and binary mobile phase solvent system separated beta-carotene, retinol, retinyl acetate, retinyl linoleate, retinyl palmitate/retinyl oleate, and retinyl stearate within a 7 min run time. Selected reaction monitoring of analytes was performed under atmospheric pressure chemical ionization in positive mode at m/z 537 -> 321 and m/z 269 -> 93 for respective [C-12]beta-carotene and [C-12]retinoids; m/z 547 -> 330 and m/z 274 -> 98 for [C-13(10)]beta-carotene and [C-13(5)] cleavage products; and m/z 279 -> 100 for metabolites of [C-13(10)]retinyl acetate. A single one-phase solvent extraction, with no saponification or purification steps, left retinyl esters intact for determination of intestinally-derived retinol in chylomicrons versus retinol from the liver bound to retinol binding protein. Coadministration of [C-13(10)]retinyl acetate with [C-13(10)]beta-carotene not only acts as a reference dose for inter-individual variations in absorption and chylomicron clearance rates, but also allows for simultaneous determination of an individual's vitamin A status.

  DOI：

  10.1194/jlr.d040204

文献信息

• Methods for treatment of dermatological conditions
  申请人：Wang Bing

  公开号：US20050032751A1

  公开（公告）日：2005-02-10

  A method of reducing the appearance of skin conditions associated with loss of skin tightness, skin firmness, or dark circles under the eyes with topical compositions comprising compounds of any of the Formulae I or Ia as described herein, is disclosed.

  本文揭示了一种通过含有本文所述的任何Formulae I或Ia化合物的局部组合物来减少与皮肤松弛、皮肤紧致度或眼部黑眼圈相关的皮肤状况的方法。
• Method and product for skin lightening
  申请人：Unilever Home & Personal Care USA, Division of Conopco, Inc.

  公开号：US20030044362A1

  公开（公告）日：2003-03-06

  A method and cosmetic product for lightening skin is provided, the method including wiping the skin with a cosmetic towelette. Impregnated on the towelette is an alpha-hydroxy carboxylic acid or salt thereof and a sunscreen agent.

  提供一种用于美白皮肤的方法和化妆品产品，该方法包括用化妆湿巾擦拭皮肤。湿巾上浸渍有α-羟基羧酸或其盐以及防晒剂。
• Chroman derivatives as lipoxygenase inhibitors
  申请人：Zhang Wei

  公开号：US20060193797A1

  公开（公告）日：2006-08-31

  The present invention is concerned with certain novel derivatives of Formula I: wherein X and R 1 to R 10 are as described in the specification, and where either R 5 is OH, —NR d OR a or —NR d —NR b R c , or R 7 is —NR d OR a or —NR d —NR b R c , or C═R 7 R 8 is C═NOR a or C═N—NR b R c , which may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful in the manufacture of skin care and/or pharmaceutical compositions for the treatment of lipoxygenase mediated disorders.

  本发明涉及Formula I的某些新颖衍生物：其中X和R1至R10如规范中所述，其中R5为OH，—NRdORa或—NRd—NRbRc之一，或R7为—NRdORa或—NRd—NRbRc之一，或C═R7R8为C═NORa或C═N—NRbRc，这些可能在制造用于治疗通过脂氧合酶介导的疾病的药物组合物中有用。它们还可能在制造用于治疗脂氧合酶介导疾病的皮肤护理和/或药用组合物中有用。
• Preparation of retinyl esters
  申请人：Eastman Chemical Company

  公开号：US07566795B2

  公开（公告）日：2009-07-28

  Long-chain esters of retinol are prepared via a chemoenzymatic process from short-chain retinyl esters and an appropriate long-chain acid or ester in the presence of an enzyme. Use of various additives enhance the yield of the desired ester and facilitated its purification.

  长链视黄醇酯是通过在酶的存在下，从短链视黄醇酯和适当的长链酸或酯经化酶过程制备而成的。使用各种添加剂可以增加所需酯的产量，并促进其纯化。
• [EN] NOVEL RETINOL DERIVATIVE AND COSMETIC COMPOSITION COMPRISING THE SAME<br/>[FR] NOUVEAU DERIVE DE RETINOL ET COMPOSITION COSMETIQUE COMPRENANT LEDIT DERIVE
  申请人：COREANA COSMETICS CO LTD

  公开号：WO2004054992A1

  公开（公告）日：2004-07-01

  The present invention relates to a novel retinol derivative and a cosmetic composition comprising the same, in particular, to a novel retinol derivative represented by the formula (I) exhibiting the effects from both L-ascorbic acid and retinol as well as being free from the disadvantages of two compounds such as skin irritation and instability in cosmetic formulation, and a cosmetic composition comprising the retinol derivative. (I)

  本发明涉及一种新型视黄醇衍生物和包含该衍生物的化妆品组合物，具体来说，涉及一种由式(I)表示的新型视黄醇衍生物，展现出L-抗坏血酸和视黄醇的双重效果，并且不具有两种化合物的缺点，如皮肤刺激和在化妆品配方中的不稳定性，以及包含该视黄醇衍生物的化妆品组合物。 (I)